Heat Biologics Inc. buy melinda
Start price
24.11.18
/
50%
€8.97
Target price
22.01.19
€12.63
Performance (%)
-4.23%
End price
22.01.19
€8.59
Summary
This prediction ended on 22.01.19 with a price of €8.59. With a performance of -4.23%, the BUY prediction by melinda finished with a loss. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Heat Biologics Inc. | 1.571% | 1.571% | -86.528% | -98.190% |
iShares Core DAX® | -0.205% | 2.949% | 17.330% | 18.203% |
iShares Nasdaq 100 | 1.613% | 5.877% | 37.451% | 56.281% |
iShares Nikkei 225® | -0.740% | -1.256% | 11.847% | 5.531% |
iShares S&P 500 | 0.267% | 3.240% | 29.308% | 46.371% |
Comments by melinda for this prediction
In the thread Heat Biologics Inc. diskutieren
SecteurRecherche biotechnologique et médicale
Operates as a clinical stage biopharmaceutical company with interest in the development of novel allogeneic drugs
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.
The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.
Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.
The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.
Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.
Nombre d'employés : 19 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Heat Biologics Inc.
Heat Biologics Inc.
Start price
Target price
Perf. (%)
€4.61
17.03.20
17.03.20
€21.00
04.11.21
04.11.21
3.99%
05.11.21
05.11.21
Heat Biologics Inc.
Start price
Target price
Perf. (%)
€66.20
13.03.17
13.03.17
€75.77
13.09.17
13.09.17
-44.67%
13.09.17
13.09.17